Article Information
History
- September 29, 2020.
Article Versions
- You are currently viewing Version 1 of this article (September 29, 2020 - 20:01).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kevin J. Forsberga,b,*,
- Danica T. Schmidtkea,
- Rachel Werthera,
- Deanna Hausmana,
- Barry L. Stoddarda,
- Brett K. Kaisera,c and
- Harmit S. Malika,b
- aDivision of Basic Sciences Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA
- bHoward Hughes Medical Institute, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 USA
- cDepartment of Biology, Seattle University, 901 12th Avenue, Seattle, WA 98122, USA
- ↵*Address correspondence to: Kevin J. Forsberg, 1100 Fairview Avenue N. A2-205, Seattle WA 98109; (206) 667-4512; email: kforsber{at}fredhutch.org
Posted September 29, 2020.
AcrIIA22 is a novel anti-CRISPR that impairs SpyCas9 activity by relieving DNA torsion of target plasmids
